REVIEW

## Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues

William V Bobo Richard C Shelton

Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA

Correspondence: William V Bobo 1500 25th Ave South, Suite 2200, Village at Vanderbilt, Nashville, TN 37212, USA Tel +1 615 327 7049 Fax +1 615 327 7093 Email william.v.bobo@vanderbilt.edu Abstract: Treatment-resistant depression (TRD) is a common occurrence in clinical practice. Up to 30% of patients with major depression do not respond to conventional antidepressant treatment, while a significantly greater number of patients experience only partial symptom reduction. Numerous strategies may be applied by the practicing clinician to overcome limitations in the effectiveness of antidepressant monotherapy, including combining drug treatment with evidence-supported psychotherapies, combining antidepressants (combination pharmacotherapy), and combining antidepressants with other non-antidepressant psychotropic medications (augmentation treatment). One such augmentation strategy, the combination of the selective serotonin reuptake inhibitor, fluoxetine (FLX), with the atypical antipsychotic drug, olanzapine (OLZ), is supported by the results of four randomized, double-blind, acute phase studies of patients who had responded inadequately to antidepressant monotherapy. In each study, the FLX/OLZ combination caused rapid reduction in Montgomery-Asberg Depression Rating scale scores, with two of the four studies showing significantly greater improvement than antidepressant monotherapy at study endpoint. Effects of the FLX/OLZ combination were strongest in cases where failure to respond to two antidepressants prior to randomization was established during the current depressive episode. The FLX/OLZ combination was well-tolerated; however, body weight gain and increases in prolactin were greater than that of the antidepressant monotherapy groups, and were comparable to that of OLZ monotherapy. While effective during acute-phase treatment, questions remain regarding the long-term efficacy and safety of FLX/OLZ relative to antidepressant monotherapy and other combination strategies. Efforts aimed at determining the placement of FLX/OLZ among the available options for addressing TRD are limited by lack of comparison and sequential treatment studies. Important aspects of study design and directions for future research are discussed.

Keywords: olanzapine, fluoxetine, combination therapy, major depression, treatment resistance

### Introduction

In the last two decades, there has been a marked increase in the number of antidepressant medications available for the treatment of major depressive disorder (MDD). In spite of this, it has become increasingly evident that the effectiveness of antidepressant monotherapy for MDD is much more modest than what was once believed. For example, a recent meta-analysis of all published double-blind placebo controlled antidepressant trials reported an antidepressant response rate of 53%.<sup>1</sup> Although this rate of response was significantly greater than the placebo response rate (36%, P < 0.05), these results have challenged the widely accepted anticipated response rates of 60% to 70% reported in prior reviews of controlled studies.<sup>2</sup>

Rates of acute and sustained symptom remission on antidepressant monotherapy are even lower, both under ideal treatment conditions that characterize randomized controlled trials, and in actual clinical treatment settings.<sup>3-5</sup> For instance, only about 30% of patients achieved clinical remission in the first phase of the landmark Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study after 12 weeks of citalopram monotherapy.6 Only about 70% of patients achieved remission after multiple rounds of medications or cognitive therapy, and the majority of patients relapsed within the first year following remission.7 The importance of this point rests in the fact that the persistence of residual depressive symptoms is associated with substantial disability and increased risk of a full depressive relapse, even among patients who achieve a positive antidepressant response and remain in active treatment.<sup>8,9</sup> As such, the majority of antidepressant-treated patients with major depression either fail to improve meaningfully or experience positive but only partial improvement. Clearly, there is an urgent need to develop safe and more effective treatments for major depressive disorder (MDD).

Until such treatments become available, numerous strategies may be applied by the practicing clinician to overcome limitations in the effectiveness of antidepressant monotherapy. In broad terms, these include combining drug treatment with evidence-supported psychotherapies,<sup>10</sup> combining antidepressants with different pharmacological profiles (combination pharmacotherapy), and combining antidepressants with psychotropic medications that are not antidepressants (augmentation treatment).<sup>11,12</sup> One such augmentation treatment approach is the combination of antidepressants with atypical antipsychotic drugs. There is now controlled evidence supporting the short-term effectiveness of atypical antipsychotic augmentation of antidepressants, including cases of difficult to treat MDD with and without psychotic features.<sup>13–15</sup> In addition, one atypical antipsychotic drug, aripiprazole, has a US Food and Drug Administration (FDA) indication as an adjunctive therapy for suboptimal antidepressant response in patients with MDD,<sup>16</sup> and one selective serotonin reuptake inhibitor (SSRI)/atypical antipsychotic combination (fluoxetine + olanzapine) is FDA approved for acute bipolar depression.<sup>17</sup> Enthusiasm for this approach is tempered by a lack of long-term effectiveness data, as well as long-term metabolic safety and tolerability concerns for many of these agents. This review is focused on the therapeutic rationale for and clinical evidence supporting the combination of fluoxetine and olanzapine for treatmentresistant MDD (TRD). Characteristics and implications of key design issues in each of the reviewed studies will be emphasized.

## **Mechanisms of action** Neurotransmitter dysfunction in major depression

A substantial body of evidence indicates that dysfunction in serotonin (5-hydroxytryptamine, 5-HT), norepinephrine (NE) and, to a lesser degree, dopamine (DA) neurotransmission are involved in the pathophysiology of major depression,18-20 and that intact 5-HT and NE neurotransmitter systems are needed in order to maintain positive clinical response to antidepressant medications. By now, it is also apparent that early theories that sought to explain the signs and symptoms of major depression solely on the basis of 5-HT and NE depletion have not provided a unifying neurobiological theory explaining why major depression occurs or how antidepressants exert their therapeutic effects. Nevertheless, the monoaminergic neurotransmitter systems have served as the most important pharmacological targets from antidepressant drug development over the last four decades.<sup>21</sup> Nearly all currently available antidepressant drugs act as potentiators of monoamine neurotransmission, either by inhibition of enzymes needed for monoamine degradation, or by blocking monoamine reuptake sites.

In recent years, a more sophisticated understanding of the pathophysiology of major depression has emerged that focuses on dysregulation of 5-HT and NE transmission rather than monoamine depletion, per se. Abnormalities in the functional activity of numerous brain regions have been identified in depressed patients using functional neuroimaging, including cortical and limbic structures that are critical for regulation of mood, emotional processing, cognitive and psychomotor functioning, and motivation,<sup>22–24</sup> all common symptoms of depression. Importantly, each of these regions receive serotonergic, noradrenergic and/or dopaminergic projections,<sup>25</sup> and abnormalities in several of these regions identified on neuroimaging have been shown to resolve following treatment with antidepressants that potentiate 5-HT and/or NE neurotransmission.<sup>26–29</sup>

#### Limitations of fluoxetine monotherapy

Monoamine neurotransmission in these key brain regions is tightly regulated, in part, by functional activity of several critical postsynaptic neuroreceptors that are not acted upon directly by SSRIs and other first-line antidepressants.

Olanzapine-fluoxetine combination in depression

Fluoxetine (FLX) and other SSRIs occupy 5-HT reuptake pumps with relatively high affinity and specificity; however, their pharmacological activity is limited, for all practical purposes, to reuptake pump blockade.<sup>30,31</sup> This poses three potential limitations that may result in a lack of meaningful clinical response to monotherapy with FLX for some patients. First, FLX does not act as a pharmacological agonist and cannot directly activate postsynaptic receptors that are important for the control of monoamine functioning in the central nervous system (CNS). Instead, FLX is dependent almost entirely on intact presynaptic serotonergic functioning.<sup>32</sup> Second, FLX has only negligible effects on NE and DA reuptake, and does not directly enhance noradrenergic or dopaminergic neurotransmission.<sup>30</sup> Furthermore, continuous SSRI treatment is associated with suppression of locus coeruleus firing,<sup>33–35</sup> resulting in decreased NE transmission. This is believed to occur as a consequence of enhanced activation of excitatory postsynaptic 5-HT2A receptors located on inhibitory GABAergic interneurons that synapse with NE neurons.<sup>36</sup> Third, SSRIs have been shown to suppress ventral tegmental area activity, and therefore reduce DA neurotransmission,<sup>37,38</sup> possibly by a 5-HT2C dependent mechanism.<sup>39-41</sup> Thus, FLX and other SSRIs may not be able to fully optimize central monoaminergic functioning as stand-alone therapies. These limitations cannot be overcome by increases in medication dosage alone.

# Augmentation with atypical antipsychotics: focus on olanzapine

The atypical antipsychotics are a pharmacologically heterogenous group of drugs. Although each is associated with a unique profile of neuroreceptor binding activity, all share the properties of high-potency postsynaptic 5-HT2A antagonism with relatively lower potency dopamine D2 receptor antagonism (or D2 partial agonist effects, in the case of aripiprazole). Importantly, the atypical antipsychotic drug, olanzapine (OLZ), is pharmacologically active at other neuroreceptors that are important for optimizing central monoamine functioning (Table 1). As such, adjunctive therapy with OLZ may be a practical means of overcoming many of the mechanistic limitations of FLX monotherapy, and improving clinical response to FLX in patients with treatment resistant major depression.

For example, 5-HT2A blockade results in numerous effects that are relevant to the activity of FLX. In the presence of 5-HT reuptake inhibition, 5-HT2A receptor antagonism has been shown to enhance 5-HT and NE release in rodents.<sup>42</sup> In preclinical models, chronic administration of FLX alone

Neuroreceptor	Pharmacological activity	Functional consequence	Possible benefit in TRD
5-HTIA	Agonist	Enhance NE release in PFC and NAcc	Improved cognitive functioning
		Increase DA release in frontal cortex and NAcc	Improved mood, cognitive functioning and motivational drive
			Overcome SSRI induced suppression of central DA activity
5-HT2A	Antagonist	Enhance 5-HT and NE release <sup>a</sup>	Reverse SSRI induced suppression of locus coeruleus firing
		Enhance DA release in PFC <sup>b</sup>	Improved regulation of mood and cognitive functioning
			Overcome SSRI induced suppression of central DA activity
5-HT2C	Antagonist	Enhance NE release in PFC and NAcc	Improved cognitive functioning
		Increase DA release in frontal cortex and NAcc	Improved mood, cognitive functioning and motivational drive
			Overcome SSRI induced suppression of central DA activity
5-HT6	Antagonist	Enhance DA release in PFC	Improved cognitive functioning
			Overcome SSRI induced suppression of centra DA activity

 Table I Selected serotonergic neuroreceptor targets of olanzapine with potential relevance for antidepressant augmentation in treatment 

 resistant depression<sup>13,42,45-47</sup>

 $^{\mathrm{a}}\mathrm{In}$  presence of 5-HT reuptake inhibition.

<sup>b</sup>In presence of weak D2 receptor antagonism.

Abbreviations: TRD, treatment-resistant depression; DA, dopamine; NE, norepinephrine; PFC, ; SSRI, selective serotonin reuptake inhibitor; NAcc, ;

suppressed locus coeruleus neuronal activity while acutely administered OLZ significantly increased locus coeruleus firing.<sup>43</sup> The combination of FLX + OLZ, however, resulted in enhanced locus coeruleus firing during both acute and chronic administration.<sup>43</sup> Increased NE release may be predicted by antagonism of the aforementioned 5-HT2A dependent reduction in NE neuronal firing, while increased NE release may then enhance 5-HT neuronal firing via activation of postsynaptic  $\alpha$ -1 adrenergic receptors in the raphe nuclei.<sup>42</sup> In addition, OLZ-associated postsynaptic 5-HT2C antagonism and 5-HT1A activation have also been shown to increase NE release in the prefrontal cortex.<sup>44</sup> Thus, the combination of FLX + OLZ may result in a greater degree of serotonergic activity than would be expected with FLX alone, and may also reverse FLX-associated NE suppression.

Interactions at serotonin receptors also have important effects on DA neurotransmission. Blockade of 5-HT2A and 5-HT6 receptors, combined with weak D2 receptor antagonism, have both been shown to enhance DA release to a greater degree than blockade of either receptor alone.<sup>45,46</sup> In addition to increasing NE efflux, OLZ effects on 5-HT2C and 5-HT1A receptors have been shown to increase DA release in the frontal cortex and nucleus accumbens,<sup>44,47</sup> brain regions that are tied to cognitive functioning and motivational drive.<sup>48</sup> Clinically, the 5-HT2A antagonists, trazodone and nefazodone, and the 5-HT1A partial agonist, gepirone, have all shown antidepressant effects in clinical trials.49-51 Augmentation of FLX with OLZ may therefore provide a means of enhancing DA activity in brain regions implicated in the pathophysiology of major depression that would not be possible with FLX alone, an effect that may be strong enough to overcome FLX-associated suppression of central DA activity and improve antidepressant response.

Finally, there has been considerable interest in the role of brain derived neurotrophic factor (BDNF), one of a number of neurotrophic factors involved in neuronal maintenance and survival,<sup>52</sup> in the both pathogenesis of major depression and the clinical response to antidepressants.<sup>53</sup> BDNF has been shown to play an important role in the susceptibility of depression-prone patients to the negative effects of stress.<sup>54</sup> In post-mortem brains of depressed patients, low levels of hippocampal and prefrontal BDNF have been documented.<sup>53</sup> Abnormally low levels of serum BDNF have also been found in patients with major depression.<sup>55</sup> It is noteworthy that long-term exposure to FLX and other antidepressants has been shown to increase BDNF production,<sup>56</sup> and that stress-induced reduction in levels of BDNF and Bcl-2, another

neurotrophic factor, may be blocked with long-term treatment with OLZ.<sup>57</sup> These results suggest that the combination of FLX + OLZ may have synergistic effects on neurotrophin activity, thereby providing an alternative mechanism by which OLZ may enhance the clinical antidepressive effects of FLX.

### **Efficacy in clinical trials** Results of acute phase studies in TRD

Five randomized, controlled trials have investigated the effect of OLZ augmentation of FLX in acute phase TRD, two of which were publised in a single paper by Thase et al.<sup>64</sup> All studies were generally similar in design (Figure 1). Patients with non-psychotic major depression and a prior history of antidepressant failure (variously defined, as discussed below) received an open-label trial of antidepressant monotherapy during a pre-randomization (lead-in) phase. Individuals who failed to achieve a pre-specified threshold of symptom response during this open-label treatment phase were then eligible for randomization to double-blind acute phase treatment with OLZ + FLX or one of several active control conditions, including continuation treatment with the leadin phase antidepressant. The design features and key results of the pre-randomization and randomized acute treatment phases of each study are summarized in Tables 2 and 3, respectively.

The first randomized, controlled study of atypical antipsychotic drug augmentation of antidepressants for TRD compared the effects of FLX + OLZ, FLX monotherapy (FLX + placebo) and OLZ monotherapy (OLZ + placebo).<sup>58</sup> There is a paucity of long-term efficacy data for the use of FLX/OLZ combination therapy for TRD. In one single-arm study,<sup>67</sup> a mixed sample of 560 patients with TRD (N = 145, defined as having history of past failure to respond to at least two trials of antidepressant treatment using agents of different pharmacological classes) and non-treatment refractory major depression (non-TRD, N = 407) received an open-label trial. Treatment resistance was confirmed by failure to achieve a partial response to open-label FLX (up to 60 mg/day) during the pre-randomization lead-in phase. Twenty-eight non-responders were then randomly assigned in a double-blind fashion to one of the three acute phase treatment conditions (see Table 3 for mean doses). Continuation of FLX monotherapy yielded no further improvement in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS),<sup>59</sup> the Hamilton Depression Rating Scale (HAM-D)<sup>60</sup> and the Clinical Global Impressions-Depression subscale (CGI-D),61




Figure I Basic design features of acute phase studies of combined fluoxetine and olanzapine (FLX/OLZ) in treatment resistant depression.<sup>58,62–64</sup> Abbreviations: FLX, fluoxetine; FLX (cont), FLX treatment continued into double-blind study phase; FLX/OLZ, fluoxetine + olanzapine combination therapy; NTP, nortriptyline; NTP (cont), NTP treatment continued into double-blind study phase; PLC, placebo; VLFX, venlafaxine.

while OLZ monotherapy achieved a modest benefit over FLX alone. The FLX/OLZ combination resulted in significantly greater improvement in depressive symptoms than FLX or OLZ alone (Table 3). The proportion of patients who achieved positive clinical response ( $\geq$ 50% improvement in MADRS scores at endpoint) was greater for the FLX/OLZ group (60%) compared with OLZ (0%) and FLX (10%) monotherapy groups. Pairwise comparisons of the proportion of those achieving positive clinical response were significant only for FLX/OLZ vs OLZ monotherapy, favoring combination therapy.

Four larger-scale randomized, double-blind multi-center studies investigating the effects of FLX/OLZ combination therapy were then completed.<sup>62–64</sup> In the first study,<sup>62</sup> 500 non-psychotically depressed patients with a prior history of failure to respond to a  $\geq$ 4 week trial of SSRI treatment and prospective failure of open-label NTP (Table 2) were randomized to one of four treatment groups for the 8-week acute phase study: FLX + OLZ, FLX monotherapy (FLX + placebo), OLZ monotherapy (OLZ + placebo), or continuation treatment with NTP (+ placebo) at the same dosage used during the pre-randomization lead-in phase (Table 3). The OLZ/FLX combination produced rapid antidepressant effect and statistically superior improvement in MADRS scores compared with all monotherapy groups through the first four weeks of treatment; however, there were no significant differences between these groups at study endpoint. There were also no significant differences between the FLX + OLZ, FLX monotherapy, OLZ monotherapy, or NTP monotherapy groups in Hamilton Anxiety Scale (HAM-A)<sup>65</sup> or Clinical Global Impressions-Illness Severity subscale scores,<sup>61</sup> or rates of categorical treatment response (27.5%, 28.9%, 19.3%, and 30.3%, respectively) or remission (16.9%, 13.3%, 12.9%, and 18.2%, respectively), at study endpoint.

The second large-scale study compared the clinical effects of OLZ/FLX combination,<sup>63</sup> FLX monotherapy, OLZ monotherapy, and VLFX monotherapy over 12 weeks in a cohort of non-psychotically depressed patients (N = 483) with a past history of failure to respond to a  $\geq$ 6 week therapeutic SSRI trial and prospective failure of an open-label lead-in trial of VLFX (Table 2). Again, there was

Study	Diagnosis	Retrospective failure	Prospective failure (lead-in)	z	Mean/mean modal dose (mg/day)	No. (%) responders (lead-in)	No. (%) randomized to double-blind
					)		treatment
Shelton et al <sup>58</sup>	DSM-IV (MDD, recurrent, without psychotic features)	Failure to respond to AD of two or more different classes (one non-SSRI). each ≥4 weeks.	Open-label FLX (20–60 mg/day), 6 weeks	34	R	l (2.9)	28 (82.4)
		at "acceptable" doses, current episode	Response = Reduction in HAM-D-21 score by ≥30%				
Shelton et al <sup>62</sup>	DSM-IV (MDD, without psychotic features) with SCID-I confirmation	Past failure to respond to SSRI (≥4 week trial), at therapeutic doses <sup>a</sup>	Open-label trial of NTP (75–175 mg/day), 7 weeks	946	R	167 (17.7)	500 (52.9)
			Response = Reduction in MADRS score by $\ge 30\%$				
Corya et al <sup>63</sup>	DSM-IV (MDD, single episode or recurrent, without psychotic features)	Past failure to respond to SSRI (≥6 week trial), at therapeutic doses²	Open-label trial of VLFX (75–375 mg/day), 7 weeks	807	<b>226 ± 100</b>	200 (26.3)	483 (59.9)
	<b>`</b>		Response = Reduction in MADRS score by $\ge 30\%$				
Thase et al <sup>64</sup>	DSM-IV (MDD, recurrent, without psychotic features) with SCID-I confirmation	Failure to respond to non-SSRI AD (≥6 weeks), at therapeutic doses <sup>b</sup> current episode	Open-label trial of FLX (50 mg/day), 8 weeks	1,313	<b>47.4</b> ± 9.3	338 (28.9)	605 (46.I)
			Response = Reduction in HAM-D-17 by ≥25% or HAM-D <18 or a >15% decrease between				
			WEEKS / AIIU O				
<sup>a</sup> Defined as citalopr <sup>b</sup> Defined as paroxet <sup>c</sup> Excluding patients	Defined as citalopram 40 mg/day, fluoxetine 40 mg/day, paroxetine 40 mg/day, or sertraline 15( Defined as paroxetine 40 mg/day, venlafaxine 150 mg/day, bupropion 300 mg/day, or trazodone Excluding patients who did not complete at least 5 weeks of open-label fluoxetine treatment.	Defined as citalopram 40 mg/day, filuoxetine 40 mg/day, paroxetine 40 mg/day, or sertraline 150 mg/day. Defined as paroxetine 40 mg/day, veniafaxine 150 mg/day, bupropion 300 mg/day, or trazodone 450 mg/day. Excluding patients who did not complete at least 5 weeks of open-label fluoxetine treatment.	Defined as citalopram 40 mg/day, fluoxetine 40 mg/day, or sertraline 150 mg/day. Defined as paroxetine 40 mg/day, venlafaxine 150 mg/day, bupropion 300 mg/day, or trazodone 450 mg/day. Excluding patients who did not complete at least 5 weeks of open-label fluoxetine treatment.				-

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Study°	Study design	E		Medication use		Outcomes	
Bitleng         groups N, dose         medications         meaners         EVXOLZ > LX         N         A MADRS         EVXOLZ > OLZ         Cold         EVXOLZ > OLZ         EVXOLZ		Design	Duration	Randomization/	Comparator	Additional	Outcome	Results
Sindlorn et al <sup>16</sup> Double. 8 weeks Described of E_XOLZ N=10, NR ADORS E_XOLZ > 612.0 m/549, 0.102.2 m/540, 0.12				blinding	groups, N, dose	medications	measures	
Function         EXAINATION         APMODE         Strateging day         Area         AVX0L2S         AUX0L2S	Shelton et al <sup>58</sup>	Double-	8 weeks	Described/ not	FLX/OLZ, N = 10,	NR	<b>A MADRS</b>	FLX/OLZ > FLX and OLZ
FLX.N         I0, S2, 0, mg/dy         CGLD         EX/OLZ > 0.12           Shelton et al <sup>1</sup> Double.         8 weeks         EX/OLZ > 0.12         NetWOLZ > 0.12           Shelton et al <sup>1</sup> Double.         8 weeks         EX/OLZ > 0.12         NetWOLZ > 0.12           Shelton et al <sup>1</sup> Double.         8 weeks         EX/OLZ > 0.12         NetWOLZ > 0.12           Shelton et al <sup>1</sup> Double.         8 weeks         EX/OLZ > 0.12         NetWOLZ > 0.12           Corps et al <sup>1</sup> Double.         12 weeks         EX/OLZ > 0.12         NetWOLZ > 0.12           Corps et al <sup>1</sup> Double.         12 weeks         Described         8.103.5 mg/dy         NetWOLZ > 0.12           Corps et al <sup>12</sup> Double.         12 weeks         Described         0.03.37 mg/dy         Response         EV/OLZ > 0.12           Corps et al <sup>12</sup> Double.         12 weeks         Described         0.03.37 mg/dy         NetWord         EV/OLZ > 0.12           Corps et al <sup>12</sup> Double.         12 weeks         Described         0.02.12         EZD RN.up         EV/OLZ > 0.12           NEX         Double.         12 weeks         Double.         EX.N = 6.0.37 mg/dy         NetWord         EV/OLZ > 0.12           NEX		blind RCT		described	52.0/13.5 mg/day		∆ HAM-D	$\wedge$
Shefton et al <sup>14</sup> Double- Shefton et al <sup>14</sup> Double- Bind RCT a Rux (arcrited RCLX) = 8.1.3.5 mg/day up to 2 mg/day) Bind RCT det results and recrited 8.33.6 mg/day up to 2 mg/day (arX) AMARS RUXOLZ > FLX (arX) (ar					FLX, $N = 10$ , 52.0 mg/day		∆ CGI-D	$\wedge$
Shefton et al <sup>16</sup> Double. 8 weeks besched EX/OLX N = 144, Lorangen PNN, Δ MADRS EX/OLZ > DLX (N = 2000 M = 1000					OLZ, N = 8, 12.5 mg/day		Response <sup>b</sup>	FLX/OLZ > OLZ
Dind RCT         described         8.335.6 mg/ay         up to 2 mg/ay         EXX012	Shelton et al <sup>62</sup>	Double-	8 weeks	Described/	FLX/OLZ, N = 146,	Lorazepam PRN,	<b>A MADRS</b>	FLX/OLZ > NTP (weeks 1–4)
FLX N = 142,358 mg/dsy     AHMA     NEXOLZ > OLZ (or segments)     NO significant benow       Corya et al <sup>10</sup> Double.     12 weeks     Described     FLX/OLZ N = 243, fixed     BZD PRN up     RX/OLZ > OLZ (or segments)     NO significant benow     NO significant benow       Corya et al <sup>10</sup> Double.     12 weeks     Described     FLX/OLZ N = 243, fixed     BZD PRN up     AMDRS     FLX/OLZ > OLZ (or ZOLZ > OLZ (or ZOLZ ) width     EXCOLZ > OLZ (or ZOL		blind RCT		described	8.5/35.6 mg/day	up to 2 mg/day)		FLX/OLZ > FLX (weeks 2–5)
FLX.N = H4, 3.3 mg/dy     Δ HAMA     No significant tensor       NTR.N = 44, 3.3 mg/dy     Δ KGLS     N/X/OLZ > OLZ (CIS)       NTR.N = 68, 10.3, mg/dy     Response     N MARS     FUX/OLZ > OLZ (V       Corpa et al <sup>10</sup> Double     12 weeks     Described     FUX/OLZ N = 243, fixed     BSZD FRN, up     No significant tensor       Corpa et al <sup>10</sup> Double     12 weeks     Described     FUX/OLZ N = 243, fixed     BSZD FRN, up     No significant tensor       Corpa et al <sup>10</sup> Double     12 weeks     Described     FUX/OLZ N = 243, fixed     BSZD FRN, up     No significant tensor       Corpa et al <sup>10</sup> Double     12 weeks     Described     GGLD     FUX/OLZ > OLZ     PUX/OLZ > OLZ       Thase et al <sup>10</sup> Double     8 weeks     Described     FUX/N = 59,     Response'     FUX/OLZ > OLZ       Thase et al <sup>10</sup> Double     8 weeks     Described     FUX/N = 59,     Response'     FUX/OLZ > OLZ       Thase et al <sup>10</sup> Double     8 weeks     Described     FUX/N = 50,     Response'     FUX/OLZ > OLZ       Thase et al <sup>10</sup> Double     8 weeks     Described     FUX/N = 50,     Response'     FUX/OLZ > FUX at ROUZ       Thase et al <sup>10</sup> Double     8 weeks     Described     FUX/N = 50,     Response'     FUX/OLZ > FUX at								FLX/OLZ > OLZ (weeks 2, 4, 6, 7)
OLZ N = 144.8.3 mg/dxy         A CGL5         A CGL5         N EXOLZ > OLZ (N = 944.8.3 mg/dxy           Corya et al <sup>10</sup> Double         12 weeks         Described/         ELXOLZ N = 44.8.3 mg/dxy         N ADRS         EXOLZ > PLX (N = 90, mission)         N Significant beave           Corya et al <sup>10</sup> Double         12 weeks         Described/         ELXOLZ N = 24.3, fixed         BZD FRN up         A MADRS         EXOLZ > PLX (N = 20, 212, mission)         N Significant beave           Corya et al <sup>10</sup> Double         12 weeks         Described/         ELXOLZ N = 27.3, mg/dxy         A MADRS         ELXOLZ > PLX (N = 20, 212, mission)         EXOLZ > 0.12         ELXOLZ > 0.12         CGL         ELXOLZ > 0.12					FLX, N = 142, 35.8 mg/day		A HAM-A	No significant between groups difference
NTRN = 64, 103.5 mg/day         Response         No significant benear           Corya et al <sup>10</sup> Double         12 weeks         Described         FLX/LN = 243, fixed         Response         No significant benear           Corya et al <sup>10</sup> bind KCT         described         FLX/LN = 40, 375 mg/day         Response         No significant benear           Corya et al <sup>10</sup> bind KCT         described         doss         LOR + mg/day         FLX/OLZ > OLZ           CLX         LUX         ads         375 mg/day         Response         FLX/OLZ > OLZ           CLX         LUX         LUX         HMM-A         FLX/OLZ > OLZ         VLX           These et al <sup>14</sup> Double         8 weeks         Double         Response         FLX/OLZ > OLZ         VLX           Thase et al <sup>14</sup> Double         8 weeks         Double         Response         FLX/OLZ > FLX an           Response         FLX/IL > 005.0 mg/day         Response         FLX/OLZ > FLX an         Response         FLX/OLZ > FLX an           Response         FLX/IL > 005.0 mg/day         Response         FLX/OLZ > FLX an         Response         FLX/OLZ > FLX an           Response         FLX/IL > 005.0 mg/day         Response         FLX/OLZ > FLX an         Response         <					OLZ, N = 144, 8.3 mg/day		A CGI-S	FLX/OLZ > OLZ (week 8)
Corya et all         Double         12 weeks         Described         ELX/OLZ: N = 243, fixed         BZD FRN, up         AMADRS         ELX/OLZ: S OLZ         VEX/OLZ: S OLZ         ELX/OLZ: S OLZ <t< td=""><td></td><td></td><td></td><td></td><td>NTP, N = 68, 103.5 mg/day<sup>c</sup></td><td></td><td>Response<sup>b</sup></td><td>No significant between groups difference</td></t<>					NTP, N = 68, 103.5 mg/day <sup>c</sup>		Response <sup>b</sup>	No significant between groups difference
Corya et al <sup>16</sup> Double         I 2 weeks         Described         FLX/OLZ N L3 (no.         FLX/OLZ > OLZ (no.         FLX/OLZ = n0.         FLX/OLZ = n0.         FLX/OLZ = n0. </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Remission<sup>d</sup></td> <td>No significant between groups difference</td>							Remission <sup>d</sup>	No significant between groups difference
bind RCT     described     does     LOR 4 mg/dy     EX/OL2 > RX (w       RXN = 60.375 mg/dy     LOR 4 mg/dy     RXN = 60.375 mg/dy     RXN = 20.375 mg/dy       RXN = 60.375 mg/dy     CGI-D     RXNOL2 > OL2       RXN = 60.375 mg/dy     RAM     RXNOL2 > OL2       OL2. N = 50, TXN (m< 59)	Corya et al <sup>63</sup>	Double-	12 weeks	Described/	FLX/OLZ, N = 243, fixed	BZD PRN, up	<b>A MADRS</b>	FLX/OLZ > OLZ (weeks 1–12)
LOR 4 mgday ELX N = 60, 375 mgday CGLD FLX N = 50, 375 mgday CGLD FLX N = 23, 79 mgday CGLD FLX N = 23, 95 mgday CGLD FLX N = 19, 8 keels CGLD FLX N = 10, 10 keels CGLD FLX N = 1		blind RCT		described	doses	to equivalent of		FLX/OLZ > FLX (weeks I–II)
FLX, N = 60, 37.5 mg/day     CGLD     FLXOLZ > 0.12       VLX, N = 50, 79 mg/day     HAMA     FLXOLZ > 0.12       VLX, N = 50, 10     VLX, N = 59, 10     Response     FLXOLZ > 0.12       VLX, N = 50, 10     VLX, N = 59, 10     Response     FLXOLZ > 0.12       VLX, N = 50, 10     Response     FLXOLZ > 0.12     2754 mg/day     Response     FLXOLZ > 0.12       Thase et al <sup>M,I</sup> Double     8 weeks     Described     FLXOLZ > 10.50 mg/day     Response     FLXOLZ > KLX an       Indo RCT     described     FLXOLZ > 19,8,7 mg/day     dose unspecified     Response     FLXOLZ > FLX an       Indo RCT     described     8.6488 mg/day     dose unspecified     Response     FLXOLZ > FLX an       Indo RCT     described     8.6485 mg/day     dose unspecified     Response     FLXOLZ > FLX an       Coccustorie     8.6488 mg/day     dose unspecified     Response     FLXOLZ > FLX an       Response     FLXOLZ = 10,7 mg/day     dose unspecified     Response     FLXOLZ > FLX an       Coccustorie     8.6488 mg/day     dose unspecified     Response     FLXOLZ > FLX an       Coccustorie     RCK     RCK     RCK     Response     FLXOLZ > FLX an       Coccustorie     RCK     RCK     RCK     RCK     RCK     RCK						LOR 4 mg/day		FLX/OLZ > VLFX (weeks 1–6)
OLZ, N = 62, 7,9 mg/day     HAM-A     FLXOLZ > OLZ       VLFX, N = 99,     VLFX, N = 99,     Response     FLXOLZ > OLZ       Thase et al <sup>14/1</sup> Double-     8 weeks     Described/     FLXOLZ > N = 98,       Thase et al <sup>14/1</sup> Double-     8 weeks     Described/     FLXOLZ > N = 98,       India RCT     described     FLXOLZ > N = 98,     BZD allowed,     AMDRS     FLXOLZ > FLX an       India RCT     described     FLXOLZ > N = 98,     BZD allowed,     AMDRS     FLXOLZ > FLX an       India RCT     described     FLXOLZ > N = 303, 49.5 mg/day     AmBRS     FLXOLZ > FLX an       Response     FLXOLZ > N = 303, 49.5 mg/day     Response     FLXOLZ > FLX an       Response     FLXOLZ > N = 303, 49.5 mg/day     Response     FLXOLZ > FLX an       Response     FLXOLZ > N = 197, 37 mg/day     Rensionf     FLXOLZ > FLX an       Response     FLXOLZ > R M = 7.0     Response     FLXOLZ > FLX an       Response     FLXOLZ > R M = 7.0     Response     FLXOLZ > FLX an       Response     FLXOLZ > R M = 7.0     Response     FLXOLZ > FLX an       Response     FLXOLZ > R M = 7.0     Response     FLXOLZ > FLX an       Response     FLXOLZ > R M = 7.0     Response     Rensione (67.2)       Response     FLXOLZ > R M = 7.0     Resp					FLX, N = 60, 37.5 mg/day		CGI-D	FLX/OLZ > OLZ
VLFX, N = 59,       VLFX, N = 59,       Response       FLX/OLZ > OLZ         Thase et al <sup>M,I</sup> Double.       8 weeks       Described/       FLX/OLZ > FLX and         Thase et al <sup>M,I</sup> Double.       8 weeks       Described/       FLX/OLZ > FLX and         Thase et al <sup>M,I</sup> Double.       8 weeks       Described/       FLX/OLZ > FLX and         Remission <sup>1</sup> FLX/OLZ > FLX and       AMADRS       FLX/OLZ > FLX and         PLX       Back       described       8.6/488 mg/day       dose unspecified       Response         FLX       Rescribed       8.6/488 mg/day       dose unspecified       Response       FLX/OLZ > FLX and         Constraint       Rescribed       8.6/488 mg/day       dose unspecified       Response       FLX/OLZ > FLX and         Rescribed       Rotation and RCT       Rescribed       8.6/488 mg/day       dose unspecified       Rescribed       Rescribed         Rescribed       Rotation and RCT       Rescribed       Rotation and RCT       Rescribed					OLZ, N = 62, 7.9 mg/day		HAM-A	FLX/OLZ > OLZ
2754 mgday     2754 mgday     Remission <sup>4</sup> FLX/OLZ > OLZ       0FC (15, N = 59, 100 mgday <sup>6</sup> 1.05 0 mgday <sup>6</sup> FLX/OLZ > FLX an       1.05 0 mgday <sup>6</sup> 1.05 0 mgday <sup>6</sup> R2D allowed, a     AMADRS     FLX/OLZ > FLX an       Thase et al <sup>#1</sup> Double     8 weeks     Described     FLX/OLZ > FLX an     Remission <sup>6</sup> FLX/OLZ > FLX an       Thase et al <sup>#1</sup> Double     8 weeks     Described     FLX/OLZ > FLX an     AMADRS     FLX/OLZ > FLX an       Dind RCT     described     8.6/48 mg/ay     dose unspecified     Remission <sup>6</sup> FLX/OLZ > FLX an       CLZ     ELX     0.1Z, N = 197, 8.7 mg/day     dose unspecified     Remission <sup>6</sup> FLX/OLZ > FLX an       CLZ     ELX     0.1Z, N = 197, 8.7 mg/day     dose unspecified     Remission <sup>6</sup> FLX/OLZ > FLX an       CLZ     ELX     0.1Z, N = 197, 8.7 mg/day     dose unspecified     Remission <sup>6</sup> FLX/OLZ > FLX an       CLZ     ELX     ELX     Inter or response     Time to response     Time to response     Time required for 2.       CLZ     ELX     Inter or response     Time to response     Time to response     FLX/OLZ > FLX an       CLZ     ELX     Inter or response     Time to response     Time to response     FLX/OLZ > FLX an       CLZ     ELX     Inte					VLFX, $N = 59$ ,		Response <sup>b</sup>	FLX/OLZ > OLZ
OFC I/S, N = 59,     BZD use     FLX > FLX/OLZ       Thase et al <sup>H/I</sup> Double-     8 weeks     NADRS     FLX/OLZ > FLX an       I0/5.0 mg/day     EX/OLZ/N = 198,     BZD allowed,     AMADRS     FLX/OLZ > FLX an       Nind KCT     described     FLX/OLZ/N = 198,     BZD allowed,     AMADRS     FLX/OLZ > FLX an       Nind KCT     described     FLX/OLZ/N = 197, 8.7 mg/day     dose unspecified     Response'     FLX/OLZ > FLX an       FLX     Response     FLX     Response'     FLX/OLZ > FLX an     Response'     FLX/OLZ > FLX an       Call     Response     FLX     Response'     FLX/OLZ > FLX an     Response'     FLX/OLZ > FLX an       Call     Response     FLX     Response'     FLX/OLZ > FLX an     Response'     FLX/OLZ > FLX an       Call     Response     Response'     Response'     FLX/OLZ > FLX an     Response'     FLX/OLZ > FLX an       Call     Response     Response'     Response'     Response'     Response'     Response'     FLX/OLZ > FLX an       Call     Response     Response'					275.4 mg/day		Remission <sup>d</sup>	FLX/OLZ > OLZ
Thase et al <sup>M,f</sup> Double-       8 weeks       Described/       FLX/OLZ > FLX and blind RCT       descriped/       descriped/       descriped/       descriped/       descriped/       descriped/       descriped/       descriped/       descriped/       descr/A (CI CI					OFC $I/5$ , $N = 59$ ,		BZD use	FLX > FLX/OLZ
Thase et al <sup>6,1</sup> Double-       8 weeks       Described/       FLX/OLZ > FLX an         blind RCT       described       8.6488 mg/day       dose unspecified       Response <sup>b</sup> FLX/OLZ > FLX an         FLX       blind RCT       described       8.6488 mg/day       dose unspecified       Response <sup>b</sup> FLX/OLZ > FLX an         FLX       an       FLX       Blind RCT       described       8.6488 mg/day       dose unspecified       Response <sup>b</sup> FLX/OLZ > FLX an         CLX       N = 203, 49.5 mg/day       An BNS       FLX       Remission <sup>6</sup> FLX/OLZ > FLX an         PLX       ELX       N       = 203, mg/day       An BNS       Response <sup>b</sup> FLX/OLZ > FLX an         CLX       N = 203, mg/day       An BNS       Response <sup>b</sup> FLX/OLZ > FLX an       An BNS         CLX       N = 204, mg/day       An BNS       Response <sup>b</sup> FLX/OLZ > FLX an       An BNS         An AD = 204, mg/day       Time to remission f       Time to response       Time required for 23       An AD BNS         An AD = 206, mg/day       Time to remission f       Time to remission f       Time to remission f       Achieve response       FLX (10 dys)         Prance       Caregorical treatment responder defined as a ≥ 206, improvement in MAD S scores from baseli					1.0/5.0 mg/day <sup>e</sup>			
blind RCT     described     8.6/48.8 mg/day     dose unspecified     Remission <sup>6</sup> FLX an       FLX. N = 203, 49.5 mg/day     Time to response     FLX/OLZ > FLX an       OLZ, N = 197, 8.7 mg/day     Time to response     FLX/OLZ > FLX an       Armine required for 23     Time to response     Armine required for 23       Armine required for 24     Time to remission.     FLX (75 days) and       Armine required for 24     Time to remission.     FLX (71 days)       Categorical treatment ender der at a = 20% inprovement.     Armine required for 24     Armine required for 24       Categorical treatment responder at monomerum MADRS scores from baseline.     Categorical treatment responder at wo consecutive MADRS scores from baseline.     Armine to remission.       Categorical treatment responder at wo consecutive MADRS foral scores = 6.     Time required for 21.     Armine required for 24.       Categorical treatment responder at wo consecutive MADRS foral scores = 6.     Armine required for 24.     Armine required for 24.       Categorical treatment responder at wo consecutive MADRS foral scores = 6.     Armine required for 24.     Armine required for 24.       Categorical treatment responder at wo consecutive MADRS foral scores = 8.     Armine status defined at store or at a control group.     Armine required for 24.       Categorical resonance or at a control group.     FLX (71 days)     Armine required for 24.     Armine required for 24.       Categor	Thase et al <sup>64,f</sup>	Double-	8 weeks	Described/	FLX/OLZ, $N = 198$ ,	BZD allowed,	A MADRS	FLX/OLZ > FLX and OLZ
FLX, N = 203, 49.5 mg/day       Remission*       FLX/OLZ > FLX an         OLZ, N = 197, 8.7 mg/day       Time to response       Time to response         CFLX (55 days) and       Time to response       Achieve response         FLX (55 days) and       Time to remission       Time to remission       Achieve response         FLX (55 days) and       Time to remission       Time required for 23       Achieve remission         Remotes: All studies were supported or sponsored by Ell Lilly and Company.       Time to remission       Time to remission       Achieve remission         Notes: All studies were supported or sponsored by Ell Lilly and Company.       Categorical treatment responder defined as a ≥ 50% improvement in MADRS scores from baseline.       Achieve remission       Time to remission       Time to remission       Achieve remission         Categorical remeter status defined as a > 50% improvement in MADRS scores from baseline.       Categorical remeter status defined as two consecutive MADRS scores scores from baseline.       Achieve remission		blind RCT		described	8.6/48.8 mg/day	dose unspecified	Response <sup>b</sup>	FLX/OLZ > FLX and OLZ
OLZ, N = 197, 8.7 mg/day       Time to response       Time to response         Achieve response       EL         CFLX (55 days) and       Time to remission         Time to remission       Time to remission         Categorical remiter       S = 50% improvement in MADRS scores from baseline.         "Categorical remiter status defined as two consecutive MADRS total scores ≤ 8.       CLZ 1 mg/FLX 5 mg/, was used as a control group.         "There were 5 dosing arm for FMOLZ. The highest 4 doss.       CLZ 1 mg/FLX 5 mg/, was used as a control group.         "Categorical remision status defined as tuno fencial concurrent studies. Poled results are repo					FLX, N = 203, 49.5  mg/day		Remission <sup>g</sup>	FLX/OLZ > FLX and OLZ
FLX (55 days) and         Time to remission         CELX (55 days) and         Time to remission         Time to remission         Time to remission         Categorial treatment responder defined as a ≥ 50% improvement in MADRS scores from baseline.         Plaan (SD) NTP plasma level by study visit ranged from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.         Categorical treatment restatus defined as a ≥ 50% improvement in MADRS scores from baseline.         Plaan (SD) NTP plasma level by study visit ranged from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.         Categorical remitter status defined as a > 50% improvement in MADRS scores ≤ 8.         "There were 5 dosing arms for FLX/OLTE heighest 4 doses were suported in Table Y.         There were 5 dosing arms for FLX/OLTE how effect a concurrent studies. Pooled results are reported in Table Y.         * fatadomized, doub-bind rind vas runa sto of elervical concurrent studies. Pooled results are reported in Table Y.         * Categorial remission status defined as MADRS total score ≤ 10 at study endoint.         * Onset of action was defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from haseline					OLZ, N = 197, 8.7 mg/day		Time to response	Time required for 25% of patients to
<ul> <li><flx (55="" and<="" days)="" p=""> <li>FLX (55 days) and     <li>Time to remission     <li>Time to remission     <li>Time required for 2:         <ul> <li>achieve remission: Fl             </li> <li>Achieve remission: Fl             </li> <li>Achieve remission: Fl             <li>Achieve remission: Fl             <li>Achieve remission: Fl             <li>Achieve remission: Fl              <li>Achieve remission: Fl             Achieve remission: Fl&lt;</li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></ul></li></li></li></li></flx></li></ul>					D			achieve response: FLX/OLZ (30 davs)
Time to remission       Time to remission         Time required for 21         Categorial reasment responder defined as a ≥ 50% improvement in MADRS scores from baseline.         *Categorial treasment responder defined as a ≥ 50% improvement in MADRS scores from baseline.         *Categorial treasment responder defined as a ≥ 50% improvement in MADRS scores from baseline.         *Categorial treasment responder defined as a ≥ 50% improvement in MADRS scores from baseline.         *Mean (5D) NTP plasma level by study visit ranged from 87.9 ± 37.5 mg/L to 114.5 ± 31.2 ng/L.         *Categorial remitter status defined as two istranged from 87.9 ± 37.5 mg/L to 114.5 ± 31.2 ng/L.         *Categorial remitter status defined as two identical consurvements in MADRS scores e.         *There were 5 dosing arms for FLX/OLZ. The highest 4 doses were pooled. The lowest dose, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), was used as a control group.         *Randomized, double-bind trial was run as two identical consurrent studies. Pooled results are reported in Table Y.         *Categorical remission status defined as MADRS total score ≤ 10 at study endpoint.         *Onset of action was defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score ≤ 25% reduction in MADRS total score from baseline								$\leq$ FLX (55 days) and OLZ (53 days)
• Categorical treatment responder defined as words of action <sup>b</sup> • CELX (171 days)         Onset of action <sup>b</sup> • CELX (171 days)         • Categorical treatment responder defined as a ≥ 50% improvement in MADRS scores from baseline.         • Categorical treatment responder defined as words: 9 = 37.5 ng/L to 114.5 = 31.2 ng/L.         • Categorical remits restruct defined as two consecutive MADRS to rest of sec. OLZ 1/5 (OLZ 1 mg/ELX 5 mg), was used as a control group.         • Categorical remits on status defined as two consecutive MADRS to results are reported in Table Y.         • Categorical remission status defined as MADRS total score ≤ 10 at study endpoint.         • Categorical remission status defined as MADRS total score ≤ 10 at study endpoint.         • Categorical remission status defined as MADRS total score ≤ 10 at study endpoint.         • Categorical remission status defined as MADRS total score ≤ 10 at study endpoint.         • Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline         • Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline         • Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline         • Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline         • Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline         • Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline         • Categorical remission status required for 50% of patients to achieve a ≥25% reduction in MADRS total score in Table         • Categorical remission s							Time to remission	Time required for 25% of patients to
<ul> <li><flx (71="" days)<="" p="">         Conset of action<sup>b</sup>         CFLX (11 days)         Onset of action<sup>b</sup>         CFLX (10:0 days)         Categorical treatment responder defined as a 26% improvement in MADRS scores from baseline.         •Categorical treatment responder defined as a 26% improvement in MADRS scores from baseline.         •Categorical treatment responder defined as a 50% improvement in MADRS scores from baseline.         •Categorical treatment responder for 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.         •Categorical remitter status defined as zwo consecutive MADRS to 14.5 ± 31.2 ng/L.         •Categorical remitter status defined as zwo consecutive MADRS to 14.5 ± 31.2 ng/L.         •Categorical remission status defined as zwo consecutive MADRS to 14.5 ± 31.2 ng/L.         •There were a constront group.         •There were scores = 8.         •There were scores = 8.         •There were scores = 0.         •There were scor</flx></li></ul>								achieve remission: FLX/OLZ (52 days)
Categorical renarment responded or sponsored by Eli Lilly and Company.       Conset of action <sup>b</sup> FLX (10.0 days)         Categorical treatment responder defined as a ≥ 50% improvement in MADRS scores from baseline.       Categorical treatment responder defined as a > 50% improvement in MADRS scores from baseline.         Mean (SD) NTP plasma level by study visit ranged from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.       Categorical remitter status defined as two consecutive MADRS scores 40%.       CALX (10.0 days)         "Mean (SD) NTP plasma level by study visit ranged from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.       CALX       CALX (10.0 days)         "Mean (SD) NTP plasma level by study visit range from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.       CALX       CALX         "There were 5 doing arms for FLX/OLZ. The highest 4 doss were pooled. The lowest dose, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), was used as a control group.       CALX         "Randomized, double-blind trial was run as two identical concurrent studies. Pooled results are reported in Table Y.       Categorical remission status defined as MDRS total score ≤ 10 at study endpoint.         "Categorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MDRS total score from baseline       Max use a score sc								<fi (71="" davs)<="" td="" x=""></fi>
<ul> <li>All studies were supported or sponsored by Eli Lilly and Company.</li> <li>b_Categorical treatment responder defined as a ≥ 50% improvement in MADRS scores from baseline.</li> <li>them (SD) NTP plasma level by study visit ranged from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L.</li> <li>there were 5 dosing arms for FLX/OLZ. The highest 4 doses were pooled. The lowest dose, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), was used as a control group.</li> <li>there were 5 dosing arms to rEX/OLZ. The highest 4 doses were pooled. The lowest dose, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), was used as a control group.</li> <li>there were 5 dosing arms for FLX/OLZ. The highest 4 doses were pooled results are reported in Table Y.</li> <li>teadomized, double-blind trial was run as two identical concurrent studies. Pooled results are reported in Table Y.</li> <li>teadegorical remission status defined as MDRS total score ≤ 10 at study endpoint.</li> <li>thore were of action was defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from haseline</li> </ul>							Onset of action <sup>h</sup>	FLX/OLZ (6.4 days) = OLZ (6.8 days)
Notes: *All studies were supported or sponsored by Eli Lilly and Company. <sup>b</sup> Categorical treatment responder defined as a ≥ 50% improvement in MADRS scores from baseline. <sup>c</sup> Mean (SD) NTP plasma level by study visit ranged from 87.9 ± 37.5 ng/L to 114.5 ± 31.2 ng/L. <sup>c</sup> Mean (SD) arms for FLX/OLZ. The highest 4 doses were pooled. The lowest dose, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), was used as a control group. <sup>c</sup> Attegorical remitter status defined as two identical concurrent studies. Pooled results are reported in Table Y. <sup>c</sup> Attegorical remission status defined as two identical concurrent studies. Pooled results are reported in Table Y. <sup>c</sup> Attegorical remission status defined as MDRS total score ≤ 10 at study endpoint. <sup>c</sup> Attegorical remission status defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline								$\leq$ FLX (10.0 days)
<sup>f</sup> Randomized, double-blind trial was run as two identical concurrent studies.Pooled results are reported in Table Y. ®Categorical remission status defined as MADRS total score ≤ 10 at study endpoint. <sup>h</sup> Onset of action was defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline	Notes: <sup>a</sup> All studies <sup>b</sup> Categorical treatm <sup>c</sup> Mean (SD) NTP pls <sup>d</sup> Categorical remitté "There were 5 dosir	were supported or : ent responder defin isma level by study v sr status defined as t g arms for FLX/OL2	sponsored by Eli Lilly ed as $a \ge 50\%$ impro <i>isit</i> ranged from 87.9 :wo consecutive MAL Z. The highest 4 dose	and Company. vement in MADRS scores frc ∂ ± 37.5 ng/L to 114.5 ± 31.2 DRS total scores ≤8. s were pooled.The lowest d	ng/L. sse, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), w	as used as a control group.		
<sup>h</sup> Onset of action was defined as time required for 50% of patients to achieve a ≥25% reduction in MADRS total score from baseline	<sup>1</sup> Randomized, doub <sup>g</sup> Categorical remissi	le-blind trial was run on status defined as	n as two identical con MADRS total score	ncurrent studies. Fooled result $\leq 10$ at study endpoint.	ts are reported in lable I.			
Abbreviations: BPRS, Brief Psychiatric Rating Scale: BZD benzodiazenine: CGI-D. Clinical Global Impressions-Depression scale: CGI-S. Clinical Global Impressions-Severity scale: FLX fluoxetine: FLX/OLZ fluoxetine + clanzapine combination	<sup>n</sup> Onset of action wa Abbreviations: BP	ts defined as time re RS. Brief Psychiatric F	equired for 50% of par Rating Scale: BZD. ben	tients to achieve a ≥25% red rzodiazenine: CGI-D. Clinical G	uction in MADRS total score from bas <sup>.</sup> 3lobal Impressions-Depression scale: CC	ieline GI-S. Clinical Global Impress	ions-Severity scale: FLX. fluoxe	tine: FLX/OLZ. fluoxetine + olanzapine combinati

Dovepress

significant early improvement associated with OLZ/FLX treatment, and significantly greater improvement in MADRS scores for OLZ/FLX over VLFX monotherapy (first 6 weeks only) and FLX monotherapy (first 11 weeks only). At study endpoint, there was no evidence of a FLX/OLZ advantage over any antidepressant monotherapy group (Table 3). This included no significant differences between FLX + OLZ, FLX monotherapy, OLZ monotherapy, and VLFX monotherapy groups in rates of categorical treatment response (43.3%, 33.9%, 25.4%, and 50.0%, respectively) or remission (29.9%, 17.9%, 13.6%, and 22.4%, respectively) at study endpoint.

The final two studies were of identical design and were run concurrently (Study 1 and Study 2). Results were reported separately and as pooled data.<sup>64</sup> Both studies were randomized, double-blind 8-week comparisons of FLX/OLZ combination therapy, FLX monotherapy (FLX + placebo) and OLZ monotherapy (OLZ + placebo) in a cohort of patients with non-psychotic major depression (N = 605, pooled data set). Eligibility was based on a past history of SSRI failure during the current depressive episode only, followed by prospective failure of an 8-week open-label FLX (50 mg/day) lead-in trial. In Study 1, there was no evidence of a superior antidepressive effect for FLX/OLZ combination treatment over either monotherapy group. However, in Study 2, the FLX/OLZ combination resulted in significantly greater improvement in MADRS scores, and in categorical response and remission rates, compared with both monotherapy groups at study endpoint. The pooled analysis of both projects revealed significantly greater improvement in MADRS scores, higher rates of categorical response (FLX + OLZ, 40.4%; FLX, 29.6%; OLZ, 25.9%) and remission (FLX + OLZ, 27.3%; FLX 16.7%; OLZ 14.7%), and shorter time required for 25% of patients to achieve therapeutic responder status (FLX + OLZ, 30 days; FLX, 55 days; OLZ, 53 days), compared with both monotherapy groups (Table 3). There were also advantages for FLX/OLZ over both antidepressant monotherapies in family and leisure functioning as measured by the Sheehan Disability Scale.<sup>66</sup> There was no statistically significant advantage observed for work functioning.

#### Results of long-term studies

There is a paucity of long-term efficacy data for the use of FLX/OLZ combination therapy for TRD. In one single-arm study,<sup>67</sup> a mixed sample of 560 patients with TRD (N = 145, defined as having history of past failure to respond to at least two trials of antidepressant treatment using agents of different

pharmacological classes) and non-treatment refractory major depression (non-TRD, N = 407) received an open-label trial FLX/OLZ (mean modal dose =  $46.1 \pm 20.7$  mg/day of FLX/7.5  $\pm$  3.5 mg/day of OLZ) for up to 76 weeks. There was a significant reduction in MADRS and CGI-S subscale scores as early as 0.5 weeks, followed by strong and continuous reductions in these measures througout the remainder of the study in both TRD and non-TRD patients. At study endpoint, 61.6% of patients met categorical response criteria  $(\geq 50\%$  reduction in MADRS scores), and 56.3% of patients achieved remission (MADRS scores of ≤8 on two consecutive visits. Higher remission rates (60.7% vs 44.1%) and shorter time to remission were observed in the non-TRD compared with TRD sample. These results were tempered by relatively high droput rates. Only 177 (31.6%) of patients completed 52 weeks of treatment, and only 143 (25.5%) of patients completed the 76-week trial. In addition, of the patients who achieved remission, 12.1% of non-TRD and 25.0% of TRD patients relapsed (defined as a MADRS score of  $\geq 16$  at any two visits following remission). More longterm studies are needed.

#### Tolerability and safety

Safety and tolerability results across each of the acute-phase studies are summarized in Table 4. Rates of discontinuation due to treatment-emergent adverse effects (TEAEs) were greatest for FLX/OLZ- and OLZ monotherapy-treated patients. Because those who did not tolerate lead-in antide-pressant medication were dropped prior to randomization, discontinuation rates tended to be lowest for drugs that were utilized during the lead-in phase and were continued during the double-blind treatment period.

Increases in body weight, total non-fasting cholesterol and serum prolactin (PRL) levels were greatest for the FLX/OLZ and OLZ groups. There was little change from baseline in any of these measures for the antidepressant monotherapy groups during double-blind treatment. The magnitude of increases in these measures between FLX/ OLZ and OLZ groups was generally similar. However, increases in total cholesterol were significantly greater for FLX + OLZ vs OLZ monotherapy in a pooled analysis of data from the 5 acute phase studies reviewed above.<sup>76</sup> There were no significant differences for change in triglyceride levels between these two groups in the Thase et al<sup>64</sup> study. There were no significant between groups differences in baseline to endpoint change in non-fasting glucose in the studies by Shelton et al<sup>62</sup> and Thase et al;<sup>64</sup> however, in both studies, the numerical increases in non-fasting glucose

		no. (%)			cnolesterol (mmol/L), mean (SD)	mean (SD)	mean (SD)		
Shelton et al <sup>58</sup>	FLX/OLZ (N = 10)	0 (0.0)	+6.7 (4.5)	1	1	1	1	1	1
	FLX (N = 10)	0 (0.0)	+0.9 (1.3)	I	I	I	I	I	I
	OLZ (N = 8)	I (25)	+6.1 (2.6)	I	I	I	I	I	I
Shelton et al <sup>62</sup>	FLX/OLZ (N = 146)	10 (6.8)	+3.3 (3.5)	7.8	+ 0.36	I	+0.36	ND <sup>a</sup>	NDª
	FLX (N = 142)	4 (2.8)	-1.42 (2.6)	0.0	+ 0.06	I	+0.05	ND <sup>a</sup>	NDª
	OLZ (N = 144)	14 (9.7)	+2.9 (3.0)	4.3	+ 0.12	I	+0.26	ND <sup>a</sup>	NDª
	NTP (N = 68)	2 (2.9)	+0.2 (3.1)	0.0	+ 0.03	I	10.0-	NDª	NDª
Corya et al <sup>63</sup>	FLX/OLZ (N = 243)	I	+4.3 (4.1)	I	+ 0.24	I	I	I	Δ N
	FLX (N = 60)	I	I	I	-0.04	I	I	I	Ω Ν
	OLZ (N = 62)	I	+3.5 (3.7)	I	-0.09	I	I	I	Δ N
	VLFX (N = 59)	I	I	I	+ 0.05	I	I	I	Δ N
	OFC 1/5 (N = 59)	I	I	I	I	I	I	I	Δ N
Thase et al <sup>64</sup>	FLX/OLZ (N = 198)	27 (13.5)	+4.9 (3.5)	I	+ 0.84 (1.8)	+ 2.2 (6.8)	+0.15 (0.5) <sup>c</sup>	+0.78 (2.7)	₽Dq
	FLX (N = 203)	5 (2.4)	+0.4 (2.3)	I	+ 0.04 (1.8)	+ 0.88 (5.4)	+0.04 (0.3) <sup>c</sup>	-0.17 (1.2)	Δů
	OLZ (N = 197)	32 (16.1)	+5.5 (3.9)	I	+ 0.15 (34.0)	+ 2.9 (10.2)	+0.22 (0.7) <sup>c</sup>	+0.46 (1.6)	Δ N

Neuropsychiatric Disease and Treatment 2009:5

levels were greatest in the FLX/OLZ and OLZ groups relative to the antidepressant monotherapy groups. Similar increases in weight ( $+5.6 \pm 6.6$  kg) and non-fasting glucose levels were reported in the long-term open-label study by Corya et al<sup>67</sup>

Extrapyramidal side effects (EPS) were measured using the Simpson-Angus Scale (SAS),68 Barnes Akathisia Scale (BARS),<sup>69</sup> and the Abnormal Involuntary Movement Scale (AIMS)<sup>70</sup> in each of the reviewed studies. There were no significant between groups differences in EPS measures in the Shelton et al<sup>62</sup> study. There were no significant changes in these measures from baseline in any of the treatment groups in the Corya et al<sup>63</sup> study, or in the FLX/OLZ group in the Thase et al<sup>64</sup> study. EPS measures for the FLX/OLZ group were reported as being similar to that of the OLZ group. In the long-term open-label study by Corya et al<sup>67</sup> there were no significant increases in SAS, BARS or AIMS scores between baseline and the 76-week study endpoint. In the only study that assessed PRL response, FLX/OLZ was associated with significantly greater increases in PRL concentration than FLX, OLZ or NTP monotherapy.62

### **Discussion** Clinical issues

TRD is a common occurrence in clinical practice, and poses numerous challenges for the practicing clinician. While atypical antipsychotic augmentation of antidepressant medication was shown to be an effective strategy for patients with TRD in a recent meta-analysis of 10 randomized, doubleblind, placebo controlled trials,14 their exact place within the mélange of therapeutic options for managing TRD has not been precisely defined. For this to be determined, data from sequential treatment studies and/or head-to-head comparisons would be needed. The largest sequential investigation of therapeutic options in TRD to date, the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study, did not investigate the effects of atypical antipsychotic augmentation. Data from head-to-head comparison trials between FLX/OLZ and other interventions for TRD are not yet available. Nevertheless, based on clinical trial results that are currently available, the strongest clinical evidence supporting a role for atypical antipsychotic drugs as augmenters of antidepressants in TRD exists for olanazapine, quetiapine and aripiprazole, at least for short-term, acute phase treatment.<sup>13,14,71-74</sup> Of these, only aripiprazole is currently approved for this indication.

Our review of the literature, which focused on the effects of OLZ augmentation of FLX in TRD, also supports the short-term efficacy of this strategy, is consistent with a prior narrative review of FLZ + OLZ in TRD.75 Effectiveness of this combination appears to be particularly strong for those with an inadequate SSRI response and treatment resistance in the current depressive episode. Focusing on this subpopulation of patients has at least two advantages. First, the decision to augment antidepressant therapy with OLZ in actual clinical practice would be based on poor treatment response to antidepressant monotherapy in the current depressive episode, rather than having a history of poor antidepressant response in prior depressive episodes. Next, the consideration of only those subjects who met treatment failure criteria during the current depressive episode would guard against the inclusion of less treatment resistant cases in studies that focus specifically on intervention effects in TRD. This would result in a sample that is more representative of the TRD population encountered in clinical practice. Patients with TRD, defined in this more stringent manner, would also have a greater likelihood of achieving a more favorable clinical response to antidepressant augmentation compared with monotherapy. This position is supported by results of Shelton et al,58 Thase et al64 and the pooled analysis by Trivedi et al76 which focused on patients with TRD based on the current depressive episode only. All showed stronger effects of FLX/OLZ augmentation relative to antidepressant monotherapy than did individual large-scale studies that used a less stringent definition of TRD.62,63

Available evidence of effectiveness FLX + OLZ in TRD is similar to the published data describing the combination's effectiveness for the short-term acute-phase treatment of depression in patients with bipolar I disorder.<sup>77,78</sup> In two randomized, controlled studies, FLX + OLZ resulted in greater 8-week improvement in depressive symptomatology compared with placebo and OLZ monotherapy,79 and greater 7-week improvement than lamotrigine.78 In addition, combination therapy with FLX + OLZ was associated with higher remission rates than placebo or OLZ monotherapy,<sup>77</sup> and a similar remission rate as lamotrigine.<sup>78</sup> In one small placebocontrolled study comparing the effects of FLX + OLZ, OLZ monotherapy, FLX monotherapy and placebo in depressed patients with bipolar I or II disorder, there were significant reductions in depressive symptoms for the entire cohort; however, the study was under-powered to detect differences between treatment groups.<sup>80</sup> In published studies of bipolar depressed patients, FLX + OLZ was generally well tolerated, with limited safety data suggesting that FLX + OLZ combination therapy was associated with weight gain and lipid and prolactin level elevation similar to that of OLZ monotherapy. As is the case with TRD, long-term safety and effectiveness

data in bipolar patients are generally lacking. FLX + OLZ combination therapy was associated with significantly greater improvement in depressive symptoms than lamotrigine in a 25-week double blind extension of the 7-week acute phase study by Brown et al.<sup>78,79</sup> However, FLZ + OLZ was associated with more frequent weight gain and significantly higher incidence of clinically significant hypercholesterolemia ( $\geq$ 240 mg/dL) and weight gain ( $\geq$ 7% increase in weight from baseline) at the 25 week endpoint.<sup>79</sup> Overall, the state of the available evidence for FLX + OLZ therapy in bipolar depression is similar to that of the combination in TRD, with encouraging results shown in short-term acute phase studies, but limited longer-term data.

Enthusiasm is thus tempered by several unanswered questions regarding the use of FLX/OLZ augmentation in TRD. The optimal augmenting dose of OLZ has not been established, though anecdotal reports and uncontrolled evidence suggest that the target dose may be lower (2.5 to 10 mg) than those used in the treatment of schizophrenia or bipolar disorder.<sup>81,82</sup> The long-term efficacy and safety profile of FLX/OLZ in TRD has also not been established. There have been no controlled investigations longer than 12 weeks to date. As such, there are also no studies focused on the question of how long OLZ augmentation of FLX is required among patients who respond acutely to the combination.

The paucity of long-term studies is also of vital clinical interest because of concerns about body weight gain and dysmetabolic effects that are associated with OLZ. Of the antipsychotic drugs, OLZ is among the most orexigenic and, with the exception of clozapine, is associated with the greatest short-term weight gain and longer-term risk of hyperglycemia, diabetes, and atherogenic dyslipidemia.<sup>83–85</sup> These metabolic risks must be carefully considered when deciding among the varied options available for augmentation of antidepressants in TRD. Apart from the obvious long-term health concerns, individuals with MDD are in physically poorer health than the general population<sup>86</sup> and therefore comprise a patient sub-population that is already at risk for profound cardiovascular morbidity and early mortality. Indeed, major depression has been identified as an independent risk factor for coronary artery disease and premature death due to cardiovascular causes.<sup>87-89</sup> As is the case with schizophrenia and bipolar disorder, psychiatric illnesses that are associated with considerable physical health burden and early mortality due to cardiovascular disease,90,91 use of OLZ for patients with major depression requires close metabolic monitoring and follow-up. The stringency of such monitoring should generally be the same that used for OLZ treatment of bipolar disorder and schizophrenia, even if lower doses of OLZ are shown to be effective for antidepressant augmentation.

## Characteristics and implications of study design and execution

The definition of TRD is a matter of ongoing debate, and numerous and varying criteria have been used to defined TRD samples in clinical trials.<sup>92</sup> To improve uniformity, several definitional models have been proposed, a detailed review of which will not be provided here. The interested reader is referred to several excellent reviews.<sup>93–95</sup> For purposes of the current discussion, some design features and issues in study execution, many of which focus on sample selection and study definitions of TRD, may have led to the inclusion of less-treatment resistant depressed patients. This could have introduced bias toward null findings in some of the reviewed studies.

For example, two of the reviewed studies based their definition of TRD, in part, on a history of failure not confined to the current depressive episode.<sup>62,63</sup> Only the studies by Shelton et al<sup>58</sup> and Thase et al<sup>64</sup> randomized patients that had both a retrospective and prospective lead-in antidepressant failure in the current depressive episode. Only the Thase et al<sup>64</sup> group randomized patients that had both a retrospective and prospective lead-in antidepressant failure in the current depressive episode only. Planned sub-group analyses of subjects in the Shelton et al<sup>62</sup> and Corya et al<sup>63</sup> studies who met both retrospective and prospective TRD inclusion criteria for the current depressive episode revealed a more marked treatment effect for FLX/OLZ. In the Corya et al63 study, improvement in MADRS at study endpoint was significantly greater for FLX/OLZ compared with FLX alone in this patient subgroup. A pooled analysis of data from all of the above reviewed acute-phase studies was performed by Trivedi et al<sup>76</sup> which focused on only those subjects with a history of antidepressant non-response in the current depressive episode (N = 1146). FLX/OLZ was associated with significantly greater 8-week improvement in MADRS scores (-13.0 vs -8.6 vs -8.2) and higher rates of remission (25.5% vs 17.3% vs 14.0%) compared with FLX or OLZ monotherapy.76

Second, although a 4- to 6-week time interval for leadin phase treatment could be considered generally adequate, many patients may require longer than this to adequately respond to antidepressant monotherapy,<sup>96</sup> a situation that may be even more problematic for drugs that require slower or more prolonged titration to therapeutic doses. These factors may have been particularly relevant for the Shelton et al<sup>62</sup> and Corya et al<sup>63</sup> studies, both of which utilized antidepressant medications during the lead-in phase that required titration to therapeutic doses (NTP and VLFX, respectively). Assuming that dosage adjustments were made during the first week even after achieving initial target doses, this would have left approximately 6 weeks of lead-in antidepressant treatment at adequate dosage. This time interval would not be sufficient to exclude late responders who, by definition, are not treatment-resistant but would have still been included in the double-blind acute treatment phase of these studies.

Third, investigators in the Shelton et al<sup>62</sup> and Corya et al<sup>63</sup> studies were not blinded to the double-blind acute phase entry criteria (reduction of  $\geq$ 30% in MADRS scores) which, as pointed out by the study authors, may have led to unconscious bias toward continued treatment and randomization via an under-rating of MADRS scores at the end of the lead-in phase. The lower than expected rates of partial treatment response at the end of the lead-in phase of both of these studies (18% and 26%, respectively) support this hypothesis; however, response rates for individuals with treatment resistant depression would also be expected to be low. In the study by Thase et al<sup>64</sup> investigators were blinded to the double-blind acute phase study entry criteria. As such, the potential limitations posed by lack of blinding to acute phase study criteria do not apply to this study.

Fourth, in each of the reviewed studies, some patients who were eligible for double-blind acute phase treatment were re-randomized to the same antidepressant medication that they received during the lead-in period. These individuals would have received up to 15 weeks of NTP treatment in the Shelton et al<sup>62</sup> study, up to 19 weeks of VLFX treatment in the Corya et al<sup>63</sup> study, and up to 16 weeks of FLX treatment in the Thase et al<sup>64</sup> study, thus causing an imbalance in study design and possible bias in favor of NTP, VLFX, or FLX, respectively. Finally, none of the reviewed studies included a placebo, as it was deemed unethical to deny active treatment to patients with refractory depression. Lack of a placebo group, however, makes it difficult to rule out non-pharmacological causes of clinical improvement across groups.

#### Summary and conclusions

TRD represents a clinical challenge for which more effective treatments are urgently needed. The combination of FLX and OLZ has shown considerable promise in short-term, acute phase studies; however, little is known about the relative effectiveness of FLX/OLZ augmentation compared with other augmenting or combination strategies for TRD. Several questions remain concerning the optimal dosing and required duration of OLZ in combination with FLX for patients with TRD, and little is known about the long-term efficacy, tolerability and safety of this combination. This includes lack of data regarding long-term effects of FLX/OLZ on surrogate markers of cardiovascular risk (weight gain, dysglycemia, atherogenic dyslipidemia) and important clinical endpoints (eg, development of diabetes and serious cardiovascular disease). Future studies of comparative effectiveness of FLX/OLZ augmentation and other forms of combination therapy for TRD are needed in order to best determine its place among existing treatment options, either in the form of head-to-head comparisons with other TRD treatment options or as a therapeutic option in sequential treatment studies of patients with major depression.

#### Information sources

PubMed, PsycINFO, Ovid MEDLINE, clinicaltrials.gov.

#### **Disclosures**

Dr Bobo has received grant/research support from Cephalon and has served on the speaker's bureau in the past for Pfizer and Janssen Pharmaceutica.

Dr Shelton has received grant/research support from Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, Inc., Sanofi-Aventis, Wyeth, Inc., AstraZeneca Pharmaceuticals, Forest Pharmaceuticals, Otsuka America, Inc., Pamlab, Inc., and Abbott Laboratories; has served as a paid consultant for Pfizer, Inc., Janssen Pharmaceutica, Eli Lilly and Co., Forest Pharmaceuticals, Otsuka America, Inc., Pamlab Inc., and Sierra Neuropharmaceuticals; and has served on the speaker's bureau in the past for Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica, Pfizer, Inc., GlaxoSmithKline, Wyeth, Inc., and Pamlab, Inc.

#### References

- Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. *Eur Neuropsychopharmacol.* 2009;19(1):34–40.
- Shelton RC. Treatment options for refractory depression. J Clin Psychiatry. 1999;60 Suppl 4:57–61.
- Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. *J Clin Psychopharmacol.* 2005 August; 25(4):336–341.
- Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. *Curr Med Res Opin*. 2006;22(9):1825–1837.
- Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. *World J Biol Psychiatry*. 2008;9(2):102–114.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*. 2006;163(1):28–40.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am J Psychiatry*. 2006;163(11):1905–1917.

- 8. Greden JF. The burden of disease for treatment-resistant depression. *J Clin Psychiatry*. 2001;62 Suppl 16:26–31.
- Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. *Biol Psychiatry*. 1998;44(5):348–360.
- Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR\*D report. *Am J Psychiatry*. 2007;164(5):739–752.
- Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J Clin Psychiatry*. 1997;58 Suppl 13:23–29.
- Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. *N Engl J Med.* 2006;354(12): 1243–1252.
- Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. *Acta Psychiatr Scand.* 2008;117(4):253–259.
- Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatmentresistant major depressive disorder: a meta-analysis. *J Clin Psychiatry*. 2007;68(6):826–831.
- Tyrka AR, Price LH, Mello MF, Mello AF, Carpenter LL. Psychotic major depression: a benefit-risk assessment of treatment options. *Drug Saf.* 2006;29(6):491–508.
- Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. *Neuropsychiatr Dis Treat*. 2008;4(5):937–948.
- Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. *Drugs.* 2008;68(8): 1115–1137.
- Jans LA, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. *Mol Psychiatry*. 2007;12(6):522–543.
- Schidkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509–522.
- Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):435–451.
- Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. *J Clin Psychiatry*. 2003;64 Suppl 13:5–12.
- Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. *Am J Psychiatry*. 2002;159(11):1830–1840.
- Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. *Am J Psychiatry*. 1999;156(5):675–682.
- Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. *Eur Neuropsychopharmacol.* 2002;12(6):527–44.
- Marek G, Duman RS. Neural circuitry and signaling in depression. In: Kaplan GB, Hammer RP, editors. *Brain Circuitry and Signaling in Psychiatry*. Washington, DC: American Psychiatric Publishing, Inc.; 2002. p. 153–178.
- Walsh ND, Williams SC, Brammer MJ, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. *Biol Psychiatry*. 2007 1;62(11):1236–1243.
- Ishizaki J, Yamamoto H, Takahashi T, Takeda M, Yano M, Mimura M. Changes in regional cerebral blood flow following antidepressant treatment in late-life depression. *Int J Geriatr Psychiatry*. 2008;23(8): 805–811.
- Vlassenko A, Sheline YI, Fischer K, Mintun MA. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. *J Neuropsychiatry Clin Neurosci.* 2004;16(3): 360–363.

- Davies J, Lloyd KR, Jones IK, Barnes A, Pilowsky LS. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. *Am J Psychiatry*. 2003;160(2):374–376.
- Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *Eur J Pharmacol.* 1997;340(2-3):249–258.
- Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. *Psychopharmacology (Berl)*. 1994;114(4):559–565.
- Rosenbaum JF, Tollefson GD. Fluoxetine. In: Schatzbert AF, Nemeroff CB, editors. *Textbook of Psychopharmacology*. Third Edition ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2004. p. 231–246.
- Szabo ST, de MC, Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. *Br J Pharmacol.* 1999;126(3):568–571.
- Sodero AP, Valdomero A, Cuadra GR, Ramirez OA, Orsingher OA. Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration. *Eur J Pharmacol.* 2004;503(1–3):35–42.
- West CH, Ritchie JC, Boss-Williams KA, Weiss JM. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. *Int J Neuropsychopharmacol.* 2009;12(5): 627–641.
- Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. *Brain Res.* 2001;922(1):9–20.
- Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. *Br J Pharmacol.* 1995;116(2):1923–1931.
- DiMascio M, DiGiovanni G, DiMatteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. *Brain Res Bull.* 1998;46(6):547–554.
- DiGiovanni G, DeDeurwaerdere P, DiMascio M, DiMatteo V, Esposito E, Spampinato U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. *Neuroscience*. 1999;91(2):587–597.
- DiMatteo V, DiGiovanni G, DiMascio M, Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. *Neuropharmacology*. 1999; 38(8):1195–1205.
- DiMatteo V, DiGiovanni G, DiMascio M, Esposito E. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. *Neuropharmacology*. 1998;37(2):265–272.
- Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. *J Clin Psychiatry.* 2005;66 Suppl 8:30–40.
- Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. *Biol Psychiatry*. 2004;55(11):1103–1109.
- 44. Gobert A, Rivet JM, Lejeune F, et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. *Synapse*. 2000;36(3):205–221.
- 45. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. *J Neurochem.* 2001;76(5):1521–1531.
- 46. Liegeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dosedependent manner. *Brain Res.* 2002;947(2):157–165.
- Ichikawa J, Meltzer HY. R(+)-8-OH-DPAT, a serotonin (1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. *J Pharmacol Exp Ther.* 1999;291(3):1227–1232.

- Jentsch JD, Roth RH, Taylor JR. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. *Prog Brain Res.* 2000;126: 433–453.
- Weisstaub NV, Zhou M, Lira A, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. *Science*. 2006; 313(5786):536–540.
- Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. *J Clin Psychiatry*. 2003;64(3):243–249.
- McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. *J Clin Psychopharmacol.* 1994; 14(5):347–352.
- 52. Barde YA. Neurotrophins: a family of proteins supporting the survival of neurons. *Prog Clin Biol Res.* 1994;390:45–56.
- Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. *Nat Neurosci.* 2007;10(9):1089–1093.
- Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry*. 2006;59(12):1116–1127.
- Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. *Biol Psychiatry*. 2008;64(6):527–532.
- Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. *Curr Opin Pharmacol.* 2007;7(1):18–21.
- Luo C, Xu H, Li XM. Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. *Brain Res.* 2004;1025(1–2):194–202.
- Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry*. 2001;158(1):131–134.
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979;134:382–389.
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
- Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Guy W, ed . 1976. Rockville, MD, U.S. Department of Health, Education, and Welfare, DHEW Publication No. (ADM) 76–338.
- Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. *J Clin Psychiatry*. 2005; 66(10):1289–1297.
- 63. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/ fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. *Depress Anxiety.* 2006;23(6): 364–372.
- Thase ME, Corya SA, Osuntokun O, et al. A randomized, doubleblind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2007;68(2):224–236.
- Hamilton M. Hamiton Anxiety Scale. ECDEU Assessment Manual for Psychopharmacology, Guy W, ed, 193–198. 1976. Rockville, MD, U.S. Department of Health, Education, and Welfare.
- Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. *Int Clin Psychopharmacol.* 1996;11 Suppl 3:89–95.
- Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. *J Clin Psychiatry*. 2003;64(11):1349–1356.
- Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand Suppl.* 1970;212:11–19.
- Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676.
- Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, 534–537. 1976. Rockville, MD, National Institute for Mental Health.

- Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2007;68(6):843–853.
- Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–165.
- 73. Thase ME. Quetiapine monotherapy for bipolar depression. *Neuropsychiatr Dis Treat.* 2008;4(1):11–21.
- Daly EJ, Trivedi MH. A review of quetiapine in combination with antidepressant therapy in patients with depression. *Neuropsychiatr Dis Treat*. 2007;3(6):855–867.
- Dodd S, Berk M. Olanzapine/fluoxetine combination for treatmentresistant depression: efficacy and clinical utility. *Expert Rev Neurother*. 2008;8(9):1299–1306.
- Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatmentresistant depression. *J Clin Psychiatry*. 2009;70(3):387–396.
- Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry*. 2003;60(11):1079–1088.
- Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, doubleblind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7):1025–1033.
- Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression. *Int J Neuropsychopharmacol.* 2008 Dec 11:1–10. [Epub ahead of print]
- Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression – lack of manic induction. *J Affect Disord*. 2005;87(1):121–130.
- Takahashi H, Kamata M, Yoshida K, Higuchi H, Ishigooka J. Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series. *Hum Psychopharmacol.* 2008;23(3):217–220.
- Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov Today. 2006;11(13–14):623–631.
- Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry*. 1999;156(11):1686–1696.
- 84. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care*. 2004;27:596–601.
- Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs*. 2005;19 Suppl 1:1–93.
- Iosifescu DV. Treating depression in the medically ill. *Psychiatr Clin* North Am. 2007;30(1):77–90.
- Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. *Psychosom Med.* 2004;66(3):305–315.
- Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. *Psychosom Med.* 2006;68(5):645–650.
- Frasure-Smith N, Lesperance F. Depression--a cardiac risk factor in search of a treatment. *JAMA*. 2003;289(23):3171–3173.
- Hennekens CH. Prevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular disease. CNS Spectr 2008; 13(6 Suppl 10):9–10.
- Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. *Psychiatr Serv.* 2009;60(2):147–156.

- Berlim MT, Turecki G. What is the meaning of treatment resistant/ refractory major depression (TRD)? A systematic review of current randomized trials. *Eur Neuropsychopharmacol.* 2007;17(11):696–707.
- Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66 Suppl 8:5–12.
- Rush AJ, Thase ME, Dube S. Research issues in the study of difficultto-treat depression. *Biol Psychiatry* 2003;53(8):743–753.
- 95. Sackeim HA. The definition and meaning of treatment-resistant depression. *J Clin Psychiatry* 2001;62 Suppl 16:10–17.
- Trivedi MH, Morris DW, Grannemann BD, Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. *J Clin Psychiatry*. 2005;66(8):1064–1070.

#### Neuropsychiatric Disease and Treatment

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peerreviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal

**Dove**press